International Urology and Nephrology

, Volume 50, Issue 7, pp 1277–1283 | Cite as

Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis

  • Patompong Ungprasert
  • Sukit Raksasuk
Nephrology - Original Paper



Patients with psoriasis may have a higher risk of developing chronic kidney (CKD) and end-stage renal disease (ESRD) compared with general population. This systematic review and meta-analysis aimed to comprehensively investigate this association by reviewing all available evidence.


A systematic review was performed using MEDLINE and EMBASE database from inception to January 2018 to identify all cohort studies that compared the risk of incident CKD and/or ESRD in patients with psoriasis versus individuals without psoriasis. Pooled risk ratio and 95% confidence interval were calculated using random-effect, generic inverse variance method.


A total of four retrospective cohort studies with 199,808 patients with psoriasis were included. The risk of incident CKD and ESRD was significantly increased among patients with psoriasis with the pooled risk ratio of 1.34 (95% CI, 1.14–1.57) and 1.29 (95% CI, 1.05–1.60), respectively.


A significantly increased risk of incident CKD and ESRD among patients with psoriasis compared with individuals without psoriasis was demonstrated in this study.


Chronic kidney disease End-stage renal disease Psoriasis Systematic review Meta-analysis 


Authors’ contributions

All authors had access to the data and a role in writing the manuscript.

Compliance with ethical standards

Conflict of interest

We do not have any financial or non-financial potential conflicts of interest.

Supplementary material

11255_2018_1868_MOESM1_ESM.doc (31 kb)
Supplementary material 1 (DOC 31 kb)
11255_2018_1868_MOESM2_ESM.docx (18 kb)
Supplementary material 2: The report of this systematic review and meta-analysis is in full compliance with the guideline meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group which is provided as supplementary data 2. (DOCX 17 kb)


  1. 1.
    Naldi L (2004) Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3:121–128CrossRefPubMedGoogle Scholar
  2. 2.
    Gisondi P (2017) High prevalence of alcohol use disorders in patients with inflammatory skin diseases applies to both psoriasis and eczema. Br J Dermatol 177:606–607CrossRefPubMedGoogle Scholar
  3. 3.
    Duffy DL, Spelman LS, Martin NG (1993) Psoriasis in Australian twins. J Am Acad Dermatol 29:428–434CrossRefPubMedGoogle Scholar
  4. 4.
    Correia B, Torres T (2015) Obesity: a key component of psoriasis. Acta Biomed 86:121–129PubMedGoogle Scholar
  5. 5.
    Naldi L, Mercuri SR (2009) Smoking and psoriasis: from epidemiology to pathomechanism. J Invest Dermatol 129:2741–2743CrossRefPubMedGoogle Scholar
  6. 6.
    Kokpol C, Aekplakorn W, Rajatanavin N (2014) Prevalence and characteristics of metabolic syndrome in South-East Asian psoriatic patients: a case-control study. J Dermatol 41:898–902CrossRefPubMedGoogle Scholar
  7. 7.
    Ungprasert P, Sanguankeo A, Upala S et al (2014) Psoriasis and venous thromboembolism: a systematic review and meta-analysis. QJM 107:793–797CrossRefPubMedGoogle Scholar
  8. 8.
    Ungprasert P, Srivali N, Kittanamongkolchai W (2016) Psoriasis and risk of incident atrial fibrillation: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol 82:489–497CrossRefPubMedGoogle Scholar
  9. 9.
    Bissonnette R, Kerdel F, Naldi L et al (2017) Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol 16:1002–1013PubMedGoogle Scholar
  10. 10.
    Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874CrossRefPubMedGoogle Scholar
  11. 11.
    Maradit-Kremers H, Nicola PJ, Crowson CS et al (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732CrossRefPubMedGoogle Scholar
  12. 12.
    Wan J, Wang S, Haynes K et al (2013) Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 347:f5961CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chiu HY, Huang HL, Li CH et al (2015) Increased risk of glomerulonephritis and chronic kidney disease in relation to severity of psoriasis, concomitant medication, and comorbidity: a nation-wide population-based cohort study. Br J Dermatol 173:146–154CrossRefPubMedGoogle Scholar
  14. 14.
    Parisi R, Rutter MK, Lunt M et al (2015) Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol 135:2189–2197CrossRefPubMedGoogle Scholar
  15. 15.
    Yu S, Tu HP, Yu CL et al (2017) Is psoriasis an independent risk factor of renal disease? A nationwide retrospective cohort study from 1996 to 2010. Dermatol Sin 35:78–84CrossRefGoogle Scholar
  16. 16.
    Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMedGoogle Scholar
  17. 17.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trial 7:177–188CrossRefGoogle Scholar
  18. 18.
    Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Ozyilmaz A, de Jong PE, Gansevoort RT (2012) Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage. Nephrol Dial Transplant 27:4046–4052CrossRefPubMedGoogle Scholar
  20. 20.
    Shahwan KT, Kimball AB (2015) Psoriasis and cardiovascular disease. Med Clin N Am 99:1227–1242CrossRefPubMedGoogle Scholar
  21. 21.
    Ogawa E, Sato Y, Minagawa A et al (2017) Pathogenesis of psoriasis and development of treatment. J Dermatol (epub ahead of pirnt)Google Scholar
  22. 22.
    Turner JE, Paust HJ, Steinmetz OM et al (2010) The Th17 immune response in renal inflammation. Kidney Int 77:1070e5CrossRefGoogle Scholar
  23. 23.
    Kitching AR, Holdsworth SR (2011) The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 22:235e8CrossRefGoogle Scholar
  24. 24.
    Imai H, Kodama T, Ishino T et al (1995) IgA nephropathy associated with hyper IgAnemia, psoriasis or pustulosis and ossification. Clin Nephrol 44:64–68PubMedGoogle Scholar
  25. 25.
    Zadrazil J, Tichy T, Horak P et al (2006) IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of ‘psoriatic nephropathy’. J Nephrol 19:382–386PubMedGoogle Scholar
  26. 26.
    Kluger N, Du-Thanh A, Bessis D et al (2015) Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol 54:e79–e80CrossRefPubMedGoogle Scholar
  27. 27.
    Kaji T, Tsukada Y, Shimada A et al (1994) Membranous nephropathy associated with psoriasis vulgaris. Clin Nephrol 42:63–64PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
  2. 2.Division of Nephrology, Department of Medicine, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand

Personalised recommendations